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ruf Oscripps . edu 9 . SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) evidence that TF is a frequent marker of advanced cancer. This project proposes to elucidate mechanisms that underlie the seemingly paradoxical observation that TF which supports metastasis under certain conditions may actually delay tumor development and local spread in breast cancer. The basic hypothesis pursued here is that the complex signaling functions of the TF cytoplasmic domain contribute to this paradox. We hope to discover new avenues to specifically interrupt breast cancer progression by unraveling the role of TF cytoplasmic domain signaling in cancer cells.
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Introduction
Tissue Factor (TF) is the cell surface receptor that activates coagulation by binding the serine protease coagulation factor Vila (Vila) . The activation of the coagulation cascade leads to thrombin generation, fibrin formation and platelet activation which together may aide tumor growth and metastasis. TF is released from tumor cells by shedding or TF comes in contact with coagulation factors when tumor cells enter the blood stream, leading to a hypercoagulable state and its clinical manifestation of spontaneous thrombosis (Trousseau's Syndrome) that occurs in several types of cancer. This provides clear evidence that TF is a frequent marker of advanced cancer. This project proposes to elucidate mechanisms that underlie the seemingly paradoxical observation that TF which supports metastasis under certain conditions may actually delay tumor development and local spread in breast cancer. The basic hypothesis pursued here is that the complex signaling functions of the TF cytoplasmic domain contribute to this paradox. We hope to discover new avenues to specifically interrupt breast cancer progression by unraveling the role of TF cytoplasmic domain signaling in cancer cells.
Body
This application has proposed two specific aims. Aim 1 is to test in A7 melanoma cells whether TF suppresses tumor growth by TF cytoplasmic domain signaling and whether WW-domain proteins are involved in this suppression by binding to the phosphorylated TF cytoplasmic domain. The review committee was concerned by the use of a melanoma cell line to study mechanisms of breast cancer development. We have responded to this conceptual weakness in continuing our survey to identify a TFnegative breast cancer cells line. We were fortunate to identify two such clones that were established in the laboratory of our colleague Dr. B. Felding-Habermann here at Scripps. These breast cancer lines are known to produce tumors in immuno-deficient mice and metastasize aggressively. Theses biological properties suggest that these cell lines may be a suitable model to study mechanisms by which TF suppresses the development of breast cancer. We made the decision to continue our studies with these cell lines, instead of melanoma cells. Fig.  1 shows FACS analysis with anti-TF antibody of these cell lines, named BMS and BCM1. Both cell lines were transfected, as proposed originally, with an expression plasmid for human TF that can be regulated by tetracycline. Stable lines were successfully generated and addition of tetracycline suppressed TF expression in BMS/TF cells by 95% and in BCM1/TF cells by 84% (Fig. 1) . Tumor growth experiments are currently ongoing in mice that do or do not receive Annual Report tetracycline in their drinking water. In this experiment, tumor growth curves for both cell lines are established and tumors are isolated upon termination of the observation period to confirm TF expression levels in the tumors. This is important to exclude a survival advantage of TF negative escape mutants. The suppression of TF expression by tetracycline administration is further confirmed.
We have recently applied our phosphorylation-specific antibody against the TF cytoplasmic domain (1) to the analysis of human pathological specimens. In ocular, diabetic neovascularization we have made the discovery that TF phosphorylation is a hallmark of TF expressed under pathological conditions, but not in normal tissues (2) . We also demonstrated in vitro that the TF cytoplasmic domain becomes phosphorylated when breast cancer cells are stimulated through PAR2 (3), established in vivo as the signaling receptor for TF (2) . Thus, tools are available to directly test whether TF becomes phosphorylated in breast cancer cells. Therefore, specimens of the currently growing tumors are also embedded for frozen sections and the phosphorylation status of TF in our breast cancer model is determined. We are continuing the proposed studies with these newly established breast cancer models with the hope to have a model of highest relevance for breast cancer biology.
Aim 2 is to generate tumor prone animals by crossing hormone sensitive C3-TAg mice with TF cytoplasmic domain deleted (TFacd/acd) mice. These crosses are progressing according to schedule. We have recently obtained male founders that lack the TF cytoplasmic domain and carry the C3-TAg transgene (Fig. 2) . We have initiated crosses of these mice with ~ 20 female tfacd/acd. Breeding of the control group was also initiated. To this end, C3-TAg wild-type mice are crossed with wild-type mice from our colony. We expect to establish a cohort of sufficient size for observation of tumor incidence and development in the upcoming year, as proposed. Cell signaling through G protein-coupled protease-activated receptors (PARs)1 is closely linked to the activation of the coagulation protease cascade (1) . Genetic evidence established an essential in vivo role of PAR signaling for platelet activation and the hemostatic response (2, 3) . However, PAR signaling also has important nonhemostatic functions in development (4), inflammation (5), and tumor biology (6) . All PARs, except for PAR2, are directly activated by thrombin, and PAR signal¬ ing is typically attributed to the action of thrombin in vivo. However, in vitro evidence indicates that thrombin receptors * This work was supported by National Institutes of Health Grants HL-16411, HL-48752, and HL-60742. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *iadvertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. are also targets for other proteases at meaningful physiological concentrations (7) (8) (9) (10) . Cellular receptors can concentrate ser¬ ine proteases at the cell surface for PAR cleavage (11) . More importantly, protease co-factors, such as tissue factor (TF) and endothelial cell protein C receptor, couple the initiation of the pro-and anti-coagulant pathways to PAR signaling by retain¬ ing transiently the initial protease products Xa and activated protein C on the cell surface (9, 10) .
Different PARs produce only partially redundant signaling responses in vascular cells. In the case of PARI and PAR2, the predominant endothelial cell expressed PARs, several immediate early gene induction events are overlapping, but only PARI sig¬ naling induces the mRNA for monocyte chemoattractant protein 1 (10) . PAR signaling induces distinct cytoskeletal effects. PARI is a potent activator of the small GTPase Rho, which leads to the disruption of intercellular junctions and to increased permeabil¬ ity of the endothelium (12, 13) . In contrast, PAR2 activation promotes cell motility by activation of the Rac4>21-activated ki¬ nase pathway and by forming a scaffolding complex containing /3-arrest in and extracellular signal-regulated kinase (ERK). This complex is implicated in pseudopodia extension and chemotaxis (14, 15) . PAR selectivity is corroborated by in vivo studies dem¬ onstrating that agonist peptides specific for PARI and PAR2 elicit selective responses in vascular tone (16, 17) and that devel¬ opmental early embryonic lethality is specific for genetic deletion of PARI (4). Thus, protease signaling specificity is in part de¬ pendent on the signal transducing PAR, but additional complex¬ ity possibly arises from the co-factors/protease receptors that assist PAR cleavage.
In the initiation phase of coagulation, TF is involved in two signaling complexes: the TF-VIIa complex that activates PAR2 and the ternary TF-VIIa-Xa complex in which Xa cleaves PARI or PAR2 (8, 9, 18, 19) . Because the ternary complex activates PARI and PAR2, it is an unresolved question whether imme¬ diate or delayed responses distinguish between TF-dependent signaling through PARI or PAR2. In this study we further characterize how the TF cytoplasmic domain becomes phosphorylated in endothelial cells. Although TF phosphorylation can be induced by phorbol 12-myristate 13-acetate (PMA) stimula¬ tion (20) (21) (22) , to date no agonist pathway of potential physio¬ logical relevance has been identified that leads to TF cytoplas¬ mic domain phosphorylation. Here, we show that PAR2 but not PARI signaling induces TF cytoplasmic domain phosphoryla¬ tion. PMA-induced TF phosphorylation in endothelial cells was found to involve PKCa-mediated phosphorylation of Ser253 (22) and subsequent phosphorylation of Ser258 by a potential Prodirected kinase (20) (21) (22) . Whereas PKCn is activated down¬ stream of PARI and PAR2 signaling, sustained membrane recruitment of PKC a is specific for PAR2 signaling and coin¬ cides with the onset of TF cytoplasmic domain phosphorylation. TF phosphorylation is a characteristic response of the initiation 23038 phase of coagulation and thus distinguishes PAR signaling in the upstream and downstream coagulation reaction.
EXPERIMENTAL PROCEDURES
Materials-Vila, inactive Ser195 to Ala Vila (iVIIa), factors IXa, X and Xa, thrombin, and PAR agonist peptides TFLLRNPNDK (PARI) and SLIGRL (PAR2) were as described (8, 9, 23) . A polyclonal goat antibody to the human TF extracellular domain and rabbit antibodies to the phosphorylated (aP-TFCD) or nonphosphorylated (a-TFCD) TF cytoplasmic domain were characterized in detail (22) . Sequencing grade trypsin (Roche Applied Science), chromogenic substrate Spectrozyme FXa (American Diagnostics, Greenwich, CT), PAR2 antibody SAM 11 and PKCa antibody (Santa Cruz Biotechnology, Santa Cruz, CA), and phospho-and non-phospho-ERKl/2 antibodies (Cell Signaling, Beverly, MA) were obtained commercially. Hirudin, conventional PKC inhibitors Go6983 and Go6976, PKC a inhibitor Safingol, and PKC/3 inhibitor Hispidin were purchased from Calbiochem (San Diego, CA). Anti-PARl antibodies ATAP2 and WEDE15 were kindly provided by Dr. L. F. Brass (24) . Recombinant nematode anticoagulant proteins 5 (NAP5) and c2 (NAPc2) (25, 26) were kindly provided by Dr. G. Vlasuk (Corvas International, San Diego, CA). Wild-type and kinase inactive PKC a (K368N) constructs were gifts from Dr. Alex Toker (Boston, MA).
Cell Culture and Transient Transfection-Chinese hamster ovary (CHO) cells expressing full-length TF (CHO/TF cells) (27) were tran¬ siently transfected by electroporation. Cells (2 X 107) in 200 jul of Dulbecco's modified Eagle's medium, 2% fetal bovine serum, 1 mM HEPES combined with 20 jug of PARI or PAR2 cDNA constructs re¬ ceived a single pulse (250 V, 500 microfarads) in a gene pulser (BioRad). The experiments were performed 48 h after transfection.
Adenoviral Vectors and Transduction of Endothelial Cells-Ad5 se¬ rotype vectors for full-length and C245S-mutated TF were described in detail (22) . Ser253 to Ala TF, generated by PCR mutagenesis, and PARI and PAR2 cDNA were similarly subcloned into adenoviral vectors. The virus was plaque-purified twice, expanded for large scale production, and purified on CsCl gradient. Human umbilical vein endothelial cells (HUVEC) were obtained from Clonetics (San Diego, CA) or Cascade Biologies (Portland, OR) and cultured in EGM medium containing 2-5% fetal bovine serum, 1 mg/ml hydrocortisone, 10 /xg/ml human epidermal growth factor, and 3 mg/ml bovine brain extract. HUVECs were trans¬ duced for 4-6 h, and the experiments were performed 48 h later. Typically, the cells were transferred to serum-free medium for 2-4 h with the fresh medium, before the agonists were added. To monitor the levels of Xa, an aliquot of culture supernatant was quenched in buffer containing EDTA and the Xa concentrations were determined by hy¬ drolysis of the chromogenic substrate Spectrozyme FXa, based on cali¬ bration curves of purified Xa.
Western Blotting and Fluorescence-activated Cell Sorter AnalysisFrom cells treated with inhibitors and agonists, TF was immunoprecipitated in the case of CHO cells and PAR 1-deficient, fibroblasts. MDA-MB-231 breast cancer cells or endothelial cells were directly lysed in reducing sample buffer for Western blot analysis with phosphorylation (aP-TFCD) or pan-specific (a-TFCD) antibody to the TF-cytoplasmic domain (22) . To assess surface expression of TF, PARI, or PAR2, the cells were harvested with EDTA and resuspended in serum-free me¬ dium, 2 mM CaCl2. To determine PAR internalization, the cells were stimulated with ternary TF-VIIa-Xa (10 nM iVIIa, 20 nM Xa, 100 nM NAPc2) complex or PAR agonist peptides for 30 min at 37 °C. Residual expression was detected by staining on ice for PARI (WEDE-15) or PAR2 (SAM 11), followed by fluorescein isothiocyanate-labeled second¬ ary antibody and flow cytometry (FACScan; Becton Dickinson, Moun¬ tain View, CA).
Translocation of PKCa from Cytosol to Membrane-Transduced, se¬ rum-starved (4 h) HUVECs were stimulated with ternary complex (iVIIa/Xa/NAPc2, 10/20/100 nM) or PMA (20 ng/ml) for 1 and 10 min and washed with ice-cold phosphate-buffered saline, 1 mM orthovanadate. The cells were harvested by scraping in 20 mM Tris-HCl, pH 7.6, 1 mM EGTA, 2 mM EDTA aprotinin (5 /xg/ml), leupeptin (10 /xg/ml), 1 mM phenylmethylsulfonyl fluoride, and sonicated twice (10 s pulse; Heat System, Ultrasonic Inc.). Cell debris was removed by centrifugation at 500 X g for 2 min, and the membrane and cytosolic fractions were separated by centrifugation of the supernatant at 100,000 X g for 1 h at 4 °C (28). The membrane fractions were resuspended in the same buffer, 1% Triton X-100, and the samples were separated by SDS-PAGE using equal protein loading for Western blotting with anti-PKCa anti¬ body. The presented data are representative of experiments repeated at least three times. The quantitations are shown as the means and standard deviations. RESULTS TF Cytoplasmic Domain Phosphorylation Is Dependent on PAR2 Signaling in Heterologous Expression Systems-PAR sig¬ naling may activate PKC, which in PMA-stimulated cells trig¬ gers TF cytoplasmic domain phosphorylation (20) (21) (22) . In TF transfected CHO (CHO/TF) cells, the TF cytoplasmic domain was phosphorylated in response to PMA stimulation, demon¬ strating expression of relevant kinases that phosphorylate TF. However, neither PARI nor PAR2 agonists induced TF cyto¬ plasmic domain phosphorylation (Fig. 1A) . CHO/TF cells ex¬ press endogenous PARI, but not PAR2 (9) . To address the role of PAR2, CHO/TF cells were transfected to express human PAR2 (CHO/TF/PAR2) (9) or uncleavable PAR2 in which the PI Arg residue was changed to Gin (CHO/TF/PAR2/P1). PAR2 agonist peptide induced TF cytoplasmic domain phosphoryla¬ tion in both cell lines (Fig. IB) . To induce TF-dependent sig¬ naling, we used NAPc2 as an experimental tool to lock in the ternary TF-VIIa-Xa complex. In the NAPc2 stabilized TFVlla-Xa complex, Vila is inhibited, but Xa is catalytically ac¬ tive and signaling competent, which mimics the characteristics of signaling in TF-initiated coagulation, where Xa is generated on cells exposed to Vila and X (9). Unlike PAR2 agonist stim¬ ulation, the NAPc2 stabilized TF-VIIa-Xa signaling complex induced TF cytoplasmic domain phosphorylation only in cells that expressed cleavage-sensitive PAR2. Thus, cleavage of PAR2 by the ternary TF-VIIa-Xa complex induces TF cytoplas¬ mic domain phosphorylation, and simply forming the ternary complex is not sufficient to induce TF cytoplasmic domain phosphorylation in PAR2-expressing cells.
To exclude the possibility that the lack of phosphorylation in response to PARI agonist stimulation in CHO/TF cells was due to low expression levels of hamster PARI, CHO/TF cells were tran¬ siently transfected with either human PARI or human PAR2. Receptor expression was confirmed by flow cytometry (Fig. 1C) . Expression of PARI or PAR2 resulted in similar PAR agonist or ternary complex-mediated ERK phosphorylation (Fig. ID) , as well as in comparable degrees of agonist-induced PARI or PAR2 internalization (Fig. IE) . These data are consistent with similar efficiency of PARI or PAR2 activation by ternary complex signal¬ ing. However, only PAR2 expression resulted in ternary complexinduced TF cytoplasmic domain phosphorylation (Fig. ID) . Thus, despite activating PARI as well as PAR2, ternary complex sig¬ naling caused TF cytoplasmic domain phosphorylation specifi¬ cally through PAR2 activation.
PAR2 Signaling Is Sufficient to Support TF Cytoplasmic Domain Phosphorylation-Because endogenous PARI was co¬ expressed in PAR2-transfected CHO cells, it remained unclear whether PARI is required, albeit not sufficient to trigger TF phosphorylation. To address this question, fibroblasts from PARl-deficient mice that also lack other PARs (9, 19) were used. PMA-stimulated TF cytoplasmic domain phosphorylation is negatively regulated by palmitoylation of the cytoplasmic Cys246 residue in endothelial cells (22) , and mutation of Cys245 greatly facilitates the detection of TF cytoplasmic domain phos¬ phorylation. PAR-1-deficient fibroblasts were co-transduced with adenovirus to express human Cys245 to Ser mutated TF together with PAR2 or PARI, achieving expression levels shown in Fig. 2A . The cells were stimulated with PARI or PAR2 agonist peptides, and with thrombin, trypsin, or ternary complex as relevant proteases that activate PARs. No TF phos¬ phorylation was observed in PARl-expressing cells, but TF cytoplasmic domain phosphorylation was observed in PAR2-transduced cells stimulated with appropriate PAR2 agonists (Fig. 2B ). These data demonstrate that endogenous PARI is not required in the signaling pathway that phosphorylates TF. Note the more quickly migrating form of TF in the loading TF cytoplasmic domain phosphorylation (fold Induction) Fig. 1 . TF cytoplasmic domain phosphorylation is mediated by PAR2 signaling in heterologous expression systems^, serum-staged CHO/TF cells were stimulated with 10 ptu PARI agonist, 100 pM PAR2 agonist, or PMA (20 ngftnl) for 1 h Immunoprecipitated TF was detected by Western blotting with anti-phosphorylated TF cytoplasmic domain antibody (oP-TFCD) or pan-specificOTh-^iytoplasrmc domain antibody(rfrrCD). B, CHO/TF cells stably expressing a noncleavable mutant of PAR2 (CHO/TF/PAR2/P1) or wild-type PAR2 (CHO/TF/PAR2) were stimulated with PAR2 agonist peptide or NAPc2-stabilized ternary TF-VIIa-Xa complex (iVIla/Xa/NAPc2 10/20/100 nM) for 1 h, followed by Western blotting for TF phosphorylation. Loading was controlled by reprobing with pan-specific anti-TF cytoplasmic domain antibody. C, tamsiently teansfected CHO/TF cells were analyzed for human PAR expression by flow cytometry using WEDE15 or SAMI 1 monoclonal antibodies to PARI or PAR2 respe(*vely Controls were stained with isotype matched primaiy antibody. D, CHO/TF cells transiently expressing human PARI or PAR2 were stimulated with ternary complex or PAR agonists for 10 min for ERK1/2 phosphorylation or for 1 h for TF cytoplasmic domain phosphorylation. The loading control in the top panel by reprobing and the anti-ERKl/2 blot were performed on separate transfers. E, left panel, quantitation of receptor mtemalization after 30 min (37 °C) stimulation by ternaiy complex or PAR agonist of CHO/TF cells transiently transfected with human PARI or; PAR2 (means and standard deviations, n -3). Right panel, the increase in TF cytoplasmic domain phosphorylation, as shown m D, was quantified by laser densitometry (means and standard deviations, n = 3). FITC, fluorescein isothiocyanate.
control that was performed by reprobing with pan-specific anti-TF cytoplasmic domain antibody. We had previously found in PMA-stimulated cells that certain iV-linked carbohydrate isoforms of TF cannot be phosphorylated (22) . The lack of phosphorylation of the more quickly migrating forms of TF in this and other experiments shown below indicates that Golgidependent carbohydrate modification, and thus presumably a certain subcellular protein trafficking route, is also important for phosphorylation of the TF cytoplasmic domain in response to PAR2 activation.
TF Cytoplasmic Domain Phosphorylation of Endogenously Expressed TF-To provide evidence that endogenously ex¬ pressed TF can be phosphorylated downstream of PAR2 signal¬ ing, we studied MDA-MB-231 cells. Under our culture condi¬ tions, this breast cancer cell line expressed fairly low levels of PAR2 but high levels of PARI and TF (Fig. 2C) . MDA-MB-231 cells were stimulated by directly adding PARI or PAR2 agonist peptides to the culture supernatant. Sustained TF cytoplasmic domain phosphorylation was observed in cell stimulated with PAR2 but not in cells stimulated with PARI agonist peptide (Fig. 2D) . The robust phosphorylation in response to PAR2 agonist peptide is remarkable, considering the fairly low levels of cell surface-expressed PAR2 relative to PARI. Thus, in cells that express endogenous TF, PARI, and PAR2, TF cytoplasmic domain phosphorylation occurs specifically downstream of PAR2 signaling.
TF Cytoplasmic Domain Phosphorylation Is Specific for Up¬ stream Coagulation Signaling in Primary Cells-The relative importance of PARI and PAR2 signaling in TF cytoplasmic domain phosphorylation was analyzed in primary HUVECs transduced with adenovirus to express TF and variable levels of PARI and PAR2. HUVECs express endogenous PARI (Fig.  aA, UD and very little PAR2 (data not shown). HUVECs were adenovirus transduced to achieve comparable expression levels of PARI or PAR2. PAR activation was confirmed by measuring internalization by flow cytometry and stimulation with the NAPc2 stabilized ternary complex similarly induced internal¬ ization of both receptors (Fig. 3J3) endogenous PARI (not shown) or overexpressed PARI did not induce TF phosphorylation (Fig. 3C) . In contrast, introducing PAR2 with TF resulted in TF cytoplasmic domain phosphoryl¬ ation after 10 min of stimulation with ternary complex, PAR2 agonist, or trypsin. Co-expression of PAR2 with Cys245 to Ser mutated TF at similar levels as wild-type TF resulted in sig¬ nificantly enhanced TF cytoplasmic domain phosphorylation after 10 min of stimulation (Fig. 3C ) and PARI stimulation was also not sufficient to induce phosphorylation of this mutant (data not shown). The differences in TF phosphorylation be¬ tween wild-type and mutant TF were quantified by densitom¬ etry, using normalization for slight differences in expression levels. TF was phosphorylated ~ 7-fold more efficiently when thioester modification of Cys246 was prevented by mutagenesis (n -3). The specificity of TF cytoplasmic domain phosphorylation in response to other coagulation proteases was analyzed in HUVECs expressing PAR2 and Cys245 to Ser mutated TF. The cells were stimulated for 1 h to increase the sensitivity for detecting inefficient responses, but high concentrations of fac¬ tor IXa and activated protein C as well as thrombin did not induce TF phosphorylation (Fig. 3D) . These are important data, because thrombin-cleaved PARI has been shown to crossactivate PAR2 (24) . Whereas the NAPc2 stabilized TF-VIIa-Xa ternary complex triggered TF cytoplasmic domain phosphoryl¬ ation with efficiency similar to that of a direct PAR2 agonist, signaling by Vila (50 nM) alone produced less efficient TF phosphorylation in HUVEC monolayers. In contrast, stimula¬ tion with Vila and X, which mimics activation of coagulation, efficiently induced TF cytoplasmic domain phosphorylation. In these experiments, Xa activity was blocked by adding a Xa inhibitor (NAP5) before free Xa reached levels that could acti¬ vate PAR2.
The efficiency of ternary complex signaling is further illus¬ trated in the middle panel of Fig. 3D with cells stimulated for only 10 min. The reaction with Vila and X generated <10 nM Xa in this time period but lead to more efficient TF phospho¬ rylation in comparison with free Xa at concentrations as high as 50 nM. In the right panel, the cells were stimulated with VHa and X in the presence of the potent Xa inhibitor NAP5. Block¬ ing Xa activity prevented TF cytoplasmic domain phosphoryl¬ ation, confirming our previous conclusions (9) that in the ter¬ nary TF-VIIa-Xa coagulation initiation complex signaling is induced by Xa and not Vila. Taken together, these experiments provide evidence that phosphorylation of the TF cytoplasmic domain occurs as a result of the activation of a highly specific signaling pathway following the initiation of coagulation.
PAR2 Signaling Induces Sustained PKCa Activation-The phosphorylation-specific antibody to TF recognizes the confor¬ mational change induced by phosphorylation of the cytoplasmic Ser258 residue that probably is the target for a Pro-directed kinase (20) (21) (22) . However, PKCa-dependent phosphorylation of Ser253 appears to be required for PMA-induced Ser258 phospho¬ rylation in HUVEC (22) . Mutation of either the PKC phospho¬ rylation site Ser253 or the PKC consensus recognition residues Lys255 abolished TF phosphorylation induced by PAR2-dependent ternary complex signaling (Fig. 4A) . TF cytoplasmic do¬ main phosphorylation was also blocked by inhibitors for con¬ ventional PKCs (a, /3, and y), Go6976, and G66983, as well the PKC a-s elective inhibitor Safingol but not the PKC/3-inhibitor Hispidin (Fig. 4B ). To further demonstrate PKC specificity, we overexpressed wild-type PKCa or kinase-inactive, Lys368 to Asn mutated PKCa constructs. Ternary complex-induced TF cytoplasmic domain phosphorylation was significantly inhib¬ ited in cells expressing dominant negative, inactive PKCa, as compared with vector control or wild-type PKCa transfected cells (Fig. 4C) . Thus, PKCa is important for TF cytoplasmic domain phosphorylation downstream of PAR2, presumably by targeting the PKC phosphorylation site at Ser253.
Thrombin-mediated PARI signaling activates PKCa in en¬ dothelial cells to increase permeability (29, 30) , but PAR2-mediated PKCa activation is poorly characterized. TF eytoplas- . Protease specificity of PAR2-dependent TF cytoplas¬ mic domain phosphorylation in endothelial cells. A, co-expression of TF and PARI or PAR2 in HUVECs. Surface expression of TF, PARI, and PAR2 was detected by flow cytometry 48 h after adenoviral trans¬ duction. Isotype-matched control staining was performed on untrans¬ duced cells. PARI (UT) depicts PARI expression levels without adeno¬ viral transduction, and PARI and PAP2 are typical expression levels obtained at the chosen virus dose. B, PARI and PAR2 internalization in HUVECs stimulated for 30 min at 37 °C with the indicated agonists was determined by flow cytometry (means and standard deviation of residual mean fluorescence, n = 3). C, HUVECs co-transduced as in A to express either wild-type TF or Cys245 to Ser mutated TF and PARI or PAR2 were stimulated for 10 min with the indicated agonists and analyzed for TF phosphorylation by Western blotting. D, left panel, TF cytoplasmic domain phosphorylation is specific for upstream coagula¬ tion protease signaling. HUVECs transduced with Cys246Ser TF and PAR2 were changed to serum-free medium and equilibrated for 2 h, followed by the addition of the indicated agonists for 1 h. 1 /xM NAP5 was added after 10 min to prevent free Xa signaling in cells stimulated with VIIa/X. Middle and right panels, cells expressing Cys245Ser TF and PAR2 were stimulated with factor X (100 iim) and Vila (10 nM) or free Xa for 10 min. NAPS was added at 1 /xM just prior to the addition of Vila and X to quench Xa activity immediately. TF cytoplasmic domain phos¬ phorylation was determined by Western blotting. Controls for TF ex¬ pression were performed on separate Western blots. For all panels, PARI agonist (10 jcxm), PAR2 agonist (100 jxm), ternary complex iVIIa/ Xa/NAPc2 (10/20/100 nM>, thrombin (20 nM), activated protein C (10 nM), trypsin, Vila alone, and IXa (50 nM) were used. For adenoviral co-transduction, wild-type and Cys246 to Ser mutated TF (200 virus particles/cell) and PARI and PAR2 (600 virus particles/cell) were used. mic domain phosphorylation induced by PAR2 agonist or ternary complex signaling occurs with somewhat delayed ki¬ netics, being undetectable 1 min and reaching maximal levels 5-10 min after stimulation (Fig. 5A) . Translocation of conven¬ tional PKCs from the cytosol to the membrane is required for their kinase activity (31) . To analyze the relation of TF cyto¬ plasmic domain phosphorylation and PKCa activation, we de¬ termined the membrane translocation of PKCa at the 1-and 10-min time points. Fig. SB shows that the ternary complex stimulated rapid (1 min) PKCa translocation from the cytosolic to the membrane fraction, but translocation was only transient and not detectable after (10 min) of stimulation of PARI ex¬ pressing cells. In contrast, the cells expressing PAR2 showed not only rapid (1 min) redistribution of PKCa to the membrane but also sustained recruitment (10 min) after ternary complex signaling. Fig. SC summarizes densitometric quantitation of repeat experiments, documenting that the prolonged PAR2-dependent translocation of PKCa was highly reproducible. PMA stimulation triggers TF cytoplasmic domain phosphorylation even in the absence of PAR2. PMA stimulation of either un¬ transduced (not shown) or PAR2-transduced endothelial cells also resulted in prolonged PKCa translocation (Fig. SB) . Taken together, these experiments provide evidence that the duration of PKCa activity at the membrane is an important determinant for TF cytoplasmic domain phosphorylation.
A critical question, therefore, is how PAR2 signaling differs from PARI activation to induce sustained PKCa translocation. G protein-coupled receptor activation induces phosphatidylinositol (PI) breakdown mediated by PI-specific phospholipase C (PLC) isoforms to generate diacylglycerol required for PKC membrane recruitment. However, diacylglycerol is also gener¬ ated by phosphatidylcholine-specific PLC (PC-PLC), which is known to promote prolonged membrane recruitment of PKCs (32) . To analyze the role of PI-and PC-PLC in PKCa activation downstream of PAR2, the effect of PLC isoform specific inhib¬ itors on TF cytoplasmic domain phosphorylation was analyzed. Whereas the PI-PLC specific inhibitor U73122 was without effect, the PC-PLC-specific inhibitor tricyclodecanoyl xanthogenate (D609) dose-dependently inhibited ternary complex-or PAR2 agonist-induced TF cytoplasmic domain phosphorylation ( Fig. 5D and data not shown). To further provide evidence that D609 inhibits the pathway downstream of PAR2 leading to PKC activation, we tested the effect of D609 on TF phospho¬ rylation by PMA, which directly activates PKC. Both D609 and U73122 only marginally reduced PMA-induced TF phosphoryl¬ ation, demonstrating that pathways downstream of PKC are not influenced by D609.
The effect of PLC isoform-specific inhibitors on PKCa trans¬ location was analyzed to clarify PAR2-mediated PKCa activa¬ tion. In PAR2 expressing cells, the PC-PLC-specific inhibitor D609 significantly inhibited both initial and sustained PKCa membrane recruitment in response to TF ternary complex sig¬ naling. U73122 produced little to no effect on PKCa transloca¬ tion in PAR2 expressing cells (Fig. SE) . Based on densitometry of three repeat experiments, D609 reduced PKCa translocation at 1 and 10 min by 76 and 77%, whereas the reduction by U73122 was 27 and 22%, respectively. In contrast, TF-dependent PARI activation resulted in transient PKCa translocation that was entirely dependent on PI-PLC. Thus, sustained acti¬ vation of PKCa and TF cytoplasmic domain phosphorylation are predominantly dependent on a PC-PLC pathway down¬ stream of PAR2 signaling.
DISCUSSION
In this study, we show that PAR2 signaling specifically tar¬ gets the TF cytoplasmic domain by inducing TF phosphoryla¬ tion. Our data demonstrate that the ternary TF-VIIa-Xa com¬ plex similarly activates PARI or PAR2, based on efficiency of PAR internalization and ERK phosphorylation, but only PAR2 signaling leads to TF phosphorylation. TF cytoplasmic domain phosphorylation is dependent on PKCa activation. The pre¬ sented mutational data support the concept that phosphoryla¬ tion of the PKC consensus Ser253 is necessary for subsequent Ser258 phosphorylation, which is recognized by the phosphoryl¬ ation-specific antibody to TF (22) . Rapid PKCa membrane re¬ cruitment downstream of PARI or PAR2 demonstrates effi¬ cient receptor activation by the ternary complex. However, only PAR2 signaling induced sustained PKCa membrane localiza¬ tion, which coincides with the somewhat delayed kinetics of TF phosphorylation. Pharmacological blockade shows that PARI and PAR2 activations recruit PKCa through distinct PLC path¬ ways. Sustained activation of PKCa downstream of PAR2 is dependent on PC-PLC, which is known to induce prolonged A, HUVECs were co-transduced with C245S, K255A, or S253A mutants of TF and PAR2 with the same virus dose as described for Fig. 2 . After 48 h, the cells were transferred to serum-free medium for 2 h and stimulated with ternary complex for 1 h. TF cytoplasmic domain phosphorylation was determined by Western blotting and reprobing with aTFCD. B, cells expressing Cys246Ser TF with PAR2 were serum-starved (2 h) and pretreated for 30 min with conventional PKC inhibitors, G66976 (1 /xM), Go6983 (1 pm), or isoform specific inhibitors for PKCa, Safingol, (50 /xm), and PKC/3, Hispidin, (10 /xM), followed by stimulation with ternary complex for 1 h at 37 °C. C, cells expressing C245S TF and PAR2 were co-transfected with 2 /xg of pcDNA3.1 (vector control), FLAG-tagged PKCa or a catalytically inactive PKCa (K368N) constructs using A, time course of ternary complex-induced TF cytoplasmic domain phosphorylation. HUVECs co-expressing C245S TF and PAR2 were transferred to serum-free medium for 2 h and stimulated with ternary complex for the indicated time. TF cytoplasmic domain phosphorylation was determined by Western blotting and reprobing with aTFCD. B, C245S TF and PAR2-or PAR 1-expressing cells were serum-starved (4 h) and stimulated with ternary complex for 1 or 10 min followed by preparation of membrane and cytosolic fractions. PKCa distribution was determined by Western blotting of samples with equal protein content. Similar loading of membrane fractions is confirmed by reprobing with a-TF (bottom panel). C, quantitation of PKCa membrane recruitment by ternary complex signaling in PAR2-or PAR 1-expressing cells. Fold inductions of translocation were determined by densitometry (means and standard deviations, n = 3). D, effect of PC-and PI-PLC-specific inhibitors on TF cytoplasmic domain phosphorylation. HUVECs expressing C245S TF and PAR2 were transferred to serum-free medium for 2 h and preincubated with the indicated concentration of the PC-PLC-specific inhibitor D609 or the PI-PLC inhibitor U73122 (10 /xm) for 30 min followed by stimulation with agonist for 1 h. In the right panel D609 was used at 20 /xM. TF cytoplasmic domain phosphorylation was determined by Western blotting, and equal TF expression was confirmed on separate blots. E, HUVECs pretreated with 20 /xM D609 or 10 /xm U73122 were stimulated, followed by membrane isolation. PKCa membrane recruitment was determined by Western blotting with a-PKCa and reprobing for confirmation of equal protein loading with a-TF. For all panels ternary complex iVIIa/Xa/NAPc2 (10/20/100 nM) and PMA (20 ng/ml) were used. membrane translocation of PKCs (32) . The fact that PMA stim¬ ulation, independent of PAR2, induces both TF phosphoryla¬ tion and sustained PKCa membrane recruitment provides fur¬ ther support for an essential role of prolonged PKCa signaling in TF cytoplasmic domain phosphorylation.
This study adds to emerging evidence (10, 12, 13 ) that PARI and PAR2 signaling elicit specific and only partially overlap¬ ping responses in endothelial cells. More importantly, only TF-dependent signaling, but not the signaling by other coagu¬ lation factors, induced cytoplasmic domain phosphorylation. The phosphorylation of the TF cytoplasmic domain thus repre¬ sents a marker for upstream coagulation signaling through PAR2. Both PAR2 and TF are induced by inflammatory medi¬ ators in endothelial cells in tissue culture (33, 34) , and TF has been detected in vivo in splenic endothelial cells in severe systemic inflammation (35) or in breast cancer-associated en¬ dothelium (36) . Moreover, PAR2 is found to be up-regulated upon differentiation of monocytes into macrophages (37) , which also express TF. Thus, PAR2-dependent phosphorylation of TF may play regulatory roles in the biology and pathology of vas¬ cular cell types that co-express TF and PAR2.
The role of the TF cytoplasmic domain has previously been analyzed in heterologous transfection systems. Deletion of the entire cytoplasmic domain has little influence on the procoagu¬ lant function of TF (27, 38, 39) and on TF-VIIa proteolytic signaling, as measured by immediate early gene induction or phosphorylation events downstream of G protein-coupled re¬ ceptor signaling (40) (41) (42) . Although the relevant PARs that transmit TF-dependent signaling in these cell models are in¬ completely defined, these studies are consistent with an inter¬ pretation that the TF cytoplasmic domain is not required for PAR activation. Our data show that TF ternary complex sig¬ naling in the case of both PARI and PAR2 signaling is rapid, leading to PKCa membrane recruitment within 1 min. How¬ ever, TF cytoplasmic domain phosphorylation is a delayed re¬ sponse, and it is therefore not surprising that the TF cytoplas¬ mic domain played apparently no role in early responses of TF-VIIa signaling. In addition, TF cytoplasmic domain phos¬ phorylation appears to be more efficient by ternary TF-VIIa-Xa in comparison with TF-VIIa stimulation, at least under our experimental conditions, which may indicate that the TF cyto¬ plasmic domain plays a regulatory role in signaling associated with activation of the coagulation pathways.
TF is important for metastasis (27, 43) , cell adhesion, and migration (44) (45) (46) (47) . Whereas PARI signaling potently induces Rho activation (12, 13) , PAR2 only transiently activates Rho while activating Rac and recruiting a j3-arrestin scaffolding complex for ERK localization (14, 15) . These pathways promote cell motility, a cellular function that is possibly supported by PAR2 signaling. PAR2 signaling that targets the TF cytoplas¬ mic domain may operate in this context, and the presented data provide novel insight into the mechanism by which PAR2 signaling feeds back onto the protease-binding receptor TF that supports PAR cleavage by associated proteases. Phosphoryla¬ tion of the TF cytoplasmic domain may influence the recruit¬ ment of adaptors and thus integrate and regulate nonhemo¬ static roles of TF in cell migration, angiogenesis, and inflammation.
